Heterogeneous Association of Alzheimer's Disease-Linked Amyloid-β and Amyloid-β Protein Precursor with Synapses

J Alzheimers Dis. 2017;60(2):511-524. doi: 10.3233/JAD-170262.

Abstract

Alzheimer's disease (AD) is increasingly viewed as a disease of synapses. Loss of synapses correlates better with cognitive decline than amyloid plaques and neurofibrillary tangles, the hallmark neuropathological lesions of AD. Soluble forms of amyloid-β (Aβ) have emerged as mediators of synapse dysfunction. Aβ binds to, accumulates, and aggregates in synapses. However, the anatomical and neurotransmitter specificity of Aβ and the amyloid-β protein precursor (AβPP) in AD remain poorly understood. In addition, the relative roles of Aβ and AβPP in the development of AD, at pre- versus post-synaptic compartments and axons versus dendrites, respectively, remain unclear. Here we use immunogold electron microscopy and confocal microscopy to provide evidence for heterogeneity in the localization of Aβ/AβPP. We demonstrate that Aβ binds to a subset of synapses in cultured neurons, with preferential binding to glutamatergic compared to GABAergic neurons. We also highlight the challenge of defining pre- versus post-synaptic localization of this binding by confocal microscopy. Further, endogenous Aβ42 accumulates in both glutamatergic and GABAergic AβPP/PS1 transgenic primary neurons, but at varying levels. Moreover, upon knock-out of presenilin 1 or inhibition of γ-secretase AβPP C-terminal fragments accumulate both pre- and post-synaptically; however earlier pre-synaptically, consistent with a higher rate of AβPP processing in axons. A better understanding of the synaptic and anatomical selectivity of Aβ/AβPP in AD can be important for the development of more effective new therapies for this major disease of aging.

Keywords: Alzheimer’s disease; amyloid-beta; gamma-secretase; synapse.

MeSH terms

  • Amyloid beta-Peptides / pharmacokinetics
  • Amyloid beta-Protein Precursor / genetics
  • Amyloid beta-Protein Precursor / metabolism*
  • Animals
  • Calcium-Calmodulin-Dependent Protein Kinase Type 1 / metabolism
  • Cells, Cultured
  • Cerebral Cortex / cytology
  • Diamines / pharmacology
  • Embryo, Mammalian
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation, Developmental / drug effects
  • Gene Expression Regulation, Developmental / genetics*
  • Glutamate Decarboxylase / metabolism
  • Humans
  • Immunohistochemistry
  • Mice
  • Mice, Transgenic
  • Microtubule-Associated Proteins / metabolism
  • Mutation / genetics
  • Neurons / cytology*
  • Neurons / drug effects
  • Neurons / ultrastructure
  • Neuropeptides / metabolism
  • Peptide Fragments / pharmacokinetics
  • Post-Synaptic Density / drug effects
  • Post-Synaptic Density / metabolism
  • Post-Synaptic Density / ultrastructure
  • Presenilin-1 / genetics
  • Presynaptic Terminals / drug effects
  • Presynaptic Terminals / metabolism
  • Presynaptic Terminals / ultrastructure
  • Protein Binding / drug effects
  • Protein Binding / genetics
  • Synapses / drug effects
  • Synapses / genetics
  • Synapses / metabolism*
  • Synapses / ultrastructure
  • Synapsins / metabolism
  • Synaptophysin / metabolism
  • Thiazoles / pharmacology
  • Time Factors
  • tau Proteins / metabolism

Substances

  • 24-diamino-5-phenylthiazole
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Diamines
  • Enzyme Inhibitors
  • Mapt protein, mouse
  • Microtubule-Associated Proteins
  • Mtap2 protein, mouse
  • Neuropeptides
  • Peptide Fragments
  • Presenilin-1
  • Synapsins
  • Synaptophysin
  • Thiazoles
  • amyloid beta-protein (1-42)
  • drebrins
  • tau Proteins
  • Calcium-Calmodulin-Dependent Protein Kinase Type 1
  • Glutamate Decarboxylase
  • glutamate decarboxylase 1